Cargando…
Targeting the Molecular and Immunologic Features of Leiomyosarcoma
SIMPLE SUMMARY: Immunotherapy has revolutionized cancer care across different cancer types. Unfortunately, leiomyosarcoma does not seem sensitive to the first-generation immune-based therapies. In this review, we present the results of trials of immunotherapy in leiomyosarcoma, emphasizing differenc...
Autores principales: | Cope, Brandon M., Traweek, Raymond S., Lazcano, Rossana, Keung, Emily Z., Lazar, Alexander J., Roland, Christina L., Nassif, Elise F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093078/ https://www.ncbi.nlm.nih.gov/pubmed/37046760 http://dx.doi.org/10.3390/cancers15072099 |
Ejemplares similares
-
Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma
por: Traweek, Raymond S., et al.
Publicado: (2022) -
Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas
por: Nassif, Elise F., et al.
Publicado: (2023) -
The Landscape of Immunotherapy for Retroperitoneal Sarcoma
por: Gingrich, Alicia A., et al.
Publicado: (2023) -
The immune landscape of undifferentiated pleomorphic sarcoma
por: Lazcano, Rossana, et al.
Publicado: (2022) -
Systematic review of anorectal leiomyosarcoma: Current challenges and recent advances
por: Nassif, Mohammed O, et al.
Publicado: (2019)